Researchers and precision-oncology experts presented new technological and mathematical advances for detecting lung cancer at medical conferences in London and through recent studies. VolitionRx Limited highlighted its Capture-Seq liquid biopsy method at ESMO MAP, while researchers explored improved screening timing and mathematical frameworks for tumor growth.
Detecting lung cancer early remains one of the primary challenges in modern oncology. Because early-stage lung cancers typically present without noticeable symptoms, clinical strategy relies heavily on screening protocols and diagnostic innovations (according to Aspirus Health reporting). Recent developments span both molecular biology and mathematical modeling, offering new tools to identify malignancies before they progress past the point of curative intervention.
Capture-Seq Technology and Early Solid Cancer Detection
VolitionRx Limited, a multi-national epigenetics company, showcased its proprietary Capture-Seq technology during a presentation at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London. Dr. Andrew Retter, a medical consultant for Volition, delivered the presentation, which focused on the detection of early-stage I solid cancers using direct ChIP-seq of short CTCF-protected plasma ctDNA.
Dr. Andrew Retter, Medical Consultant, Volition, stated that they were delighted to be selected to present in the main auditorium at that prestigious conference, adding that from a clinical perspective, the proof of concept and early blinded validation results reported were extremely encouraging, and noting that in two independent cohorts they reported no false positives and detected 49/49 cancers in the first cohort (including 23 early stage I/II and 21 healthy controls) and validated it in a second blinded cohort with 13/14 later stage cancers detected with 10 additional healthy controls.
The company also reported data from a blinded validation cohort of 81 subjects, which included 59 colorectal and lung cancer patients alongside 22 healthy controls. According to Volition, the early-stage cancer detection rate reached 95% for stage I and II cancers. Dr. Jake Micallef, Chief Scientific Officer at Volition, explained the mechanics behind the test.
Dr. Jake Micallef, Chief Scientific Officer, Volition, explained that this new method isolated CTCF-protected plasma ctDNA from background cell free DNA bound to nucleosomes, and noted that analysis of the isolated CTCF-protected ctDNA produced sequencing data sets for blood samples from early stage cancer patients that were absent from blood samples of healthy control subjects.
Volition is fast-tracking the development of Capture-Seq through further studies involving competing conditions and collaborations with oncology key opinion leaders. The company aims to position the test for multi-cancer early detection and minimal residual disease (MRD) detection and treatment monitoring.
Mathematical Modeling and the Cure Threshold in Screening
While molecular diagnostics target circulating biomarkers, mathematical research is refining when and how patients undergo routine screenings. Deborah Goldwasser, a mathematics researcher and professor at Florida International University, published findings in Cancer Epidemiology, Biomarkers & Prevention addressing statistical biases in tumor progression models (as reported by Florida International University).
Goldwasser’s research focuses on the cure threshold
, defined as the specific point where an aggressive lung cancer transitions from being surgically curable to inoperable. Traditional estimation models relied on chest X-ray data, which often missed fast-growing tumors. The introduction of low-dose CT (LDCT) scans provides significantly sharper imaging, allowing researchers to detect smaller malignancies during annual checkups.
Deborah Goldwasser, Mathematics Researcher and Professor, Florida International University, suggested that if every lethal cancer detected before the cure threshold contributes to mortality reduction, that is where one obtains the benefit of screening.
This mathematical framework builds on the foundational National Lung Screening Trial from 2010, which demonstrated that LDCT screening reduced lung cancer deaths by approximately 20 percent. Goldwasser’s work seeks to optimize screening schedules by identifying which patient cohorts benefit most from frequent monitoring and which might avoid unnecessary imaging.
Current Screening Guidelines and Clinical Recommendations
Public health institutions continue to emphasize the proven value of existing imaging technologies while researchers evaluate new blood-based biomarkers. According to the National Cancer Institute, low-dose CT screenings reduce mortality by 20% to 24% by catching the disease at treatable stages.
Thomas Oliver, Aspirus Health, noted that typically, early-stage lung cancers do not have any symptoms, explaining that screening therefore becomes really important, much like how mammography and breast cancer have changed how the survivability of breast cancer is managed, and concluding that the same is true in lung cancer.
Healthcare providers advise adults with a history of smoking to consult their primary physicians regarding eligibility for low-dose CT screenings. As biotechnology firms validate blood-based liquid biopsies like Capture-Seq and researchers refine mathematical screening thresholds, clinical management of lung cancer moves toward increasingly personalized early intervention.
